Manufactured by:ProteoGenix
Save 20%RUO

Recombinant Human ULBP1 Protein, N-His

Recombinant Human ULBP1 Protein, N-His from ProteoGenix; catalogue ARO-P11677; research use only.

SKU:
ABM142115-1
Manufacturer SKU
ARO-P11677
Product type
Recombinant Proteins
Expression systemProkaryotic expression

Manufacturer provenance

Manufactured by:
ProteoGenix
Sold by:
ABMIUM
Fulfilled from:
Manufacturer facility or confirmed fulfilment location

Know who made it. See the evidence. Buy through one marketplace.

Product description

Introduction

Recombinant Human ULBP1 Protein, also known as UL16-binding protein 1, is a member of the ULBP family of proteins. It is a type I transmembrane protein that plays a crucial role in the immune response by acting as a ligand for the NKG2D receptor on natural killer (NK) cells and cytotoxic T cells. This interaction leads to the activation of these cells and the elimination of infected or cancerous cells. In this article, we will discuss the structure, activity, and applications of Recombinant Human ULBP1 Protein.

Structure of Recombinant Human ULBP1 Protein

The gene encoding ULBP1 is located on chromosome 6 in humans and consists of 6 exons. The mature protein has a length of 233 amino acids and a molecular weight of approximately 31 kDa. It is composed of a short cytoplasmic tail, a transmembrane domain, and an extracellular domain. The extracellular domain contains three immunoglobulin-like domains, which are responsible for binding to the NKG2D receptor.

Activity of Recombinant Human ULBP1 Protein

Recombinant Human ULBP1 Protein has been shown to have potent immune-stimulating activity. It acts as a ligand for the NKG2D receptor, which is expressed on the surface of NK cells, T cells, and some subsets of γδ T cells. Upon binding of ULBP1 to NKG2D, a signaling cascade is initiated, leading to the activation of these immune cells. This activation results in the release of cytokines and chemokines, which recruit other immune cells to the site of infection or tumor. Additionally, ULBP1-NKG2D interaction leads to the direct killing of infected or cancerous cells by NK cells and cytotoxic T cells.

Applications of Recombinant Human ULBP1 Protein

Recombinant Human ULBP1 Protein has a wide range of applications in both research and clinical settings. Some of the major applications are listed below:

1. Immunotherapy

The potent immune-stimulating activity of Recombinant Human ULBP1 Protein makes it a promising candidate for immunotherapy. It can be used to enhance the immune response against cancer cells or viral infections. Several studies have shown that ULBP1-NKG2D interaction can lead to the elimination of various types of cancer cells, including melanoma, leukemia, and breast cancer. Therefore, Recombinant Human ULBP1 Protein can be used in combination with other immunotherapies to improve their efficacy.

2. Diagnostic tool

The expression of ULBP1 is upregulated in various types of cancer, making it a potential biomarker for cancer diagnosis. Recombinant Human ULBP1 Protein can be used in diagnostic tests to detect the presence of ULBP1 in patient samples, which can aid in the early detection of cancer.

3. Research tool

Recombinant Human ULBP1 Protein is widely used as a research tool to study the immune response and the role of ULBP1 in various diseases. It can be used to investigate the mechanism of action of ULBP1 and its interaction with the NKG2D receptor. Additionally, Recombinant Human ULBP1 Protein can be used to screen for potential drugs that can modulate the ULBP1-NKG2D pathway.

4. Vaccine adjuvant

Recombinant Human ULBP1 Protein has been shown to enhance the immune response against vaccines when used as an adjuvant. It can be used to improve the efficacy of vaccines against infectious diseases, such as influenza and hepatitis B.

Conclusion

In summary, Recombinant Human ULBP1 Protein is a crucial player in the immune response and has various applications in research and clinical settings. Its potent immune-stimulating activity and potential as a biomarker make it a promising candidate for immunotherapy and diagnostic tools

ProteoGenix catalogue number ARO-P11677. For research use only.

Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 23.22 kDa; Fragment: Thr30-Asp206; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet

Key facts & specifications
Also known as
Retinoic acid early transcript 1I, UL16-binding protein 1, ALCAN-beta, N2DL-1, NKG2DL1, RAET1I, N2DL1, NKG2D ligand 1, ULBP1
Host species
E. coli
Source organism
Human
Molecular weight
23.22 kDa
Sequence fragment
Thr30-Asp206
Sequence
THCLCYDFIITPKSRPEPQWCEVQGLVDERPFLHYDCVNHKAKAFASLGKKVNVTKTWEEQTETLRDVVDFLKGQLLDIQVENLIPIEPLTLQARMSCEHEAHGHGRGSWQFLFNGQKFLLFDSNNRKWTALHPGAKKMTEKWEKNRDVTMFFQKISLGDCKMWLEEFLMYWEQMLD
Technical note
For research use only.
Identifiers & database references
Manufacturer SKU
ARO-P11677
UniProt accession
Q9BZM6
Storage, stability & shipping
Storage conditions
4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection)
Shipped at
Dry Ice
Compliance & documents
ISO certifications
ISO 9001:2023, ISO 14001: 2023
Datasheet
Open datasheet
Frequently asked questions
Who manufactured this product?

This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.

Can ABMIUM ship this product internationally?

ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.

Can I check suitability before ordering?

Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.

Is this product for clinical use?

Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.

ProteoGenix
$215.00$172.00